^
    over2years
    KRAS wild-type pancreatic ductal adenocarcinoma: Molecular and therapeutic opportunities. (ASCO 2022)
    4 pts received FOLFIRINOX (FFX), 2 gemcitabine/nab-paclitaxel (GP) and tumor response were comparable to previously reported results. 1 received 1st-line pembrolizumab and remained on therapy at the time of analysis... The molecular profile of KRAS wt PDAC is highly heterogeneous and difficult to generalize. Novel approaches (e.g., basket trials) are needed to develop therapy for this rare PDAC subgroup.
    Tumor Mutational Burden • MSi-H Biomarker • PD(L)-1 Biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • EML4 (EMAP Like 4) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MGMT (6-O-methylguanine-DNA methyltransferase) • CCNE1 (Cyclin E1) • KMT2D (Lysine Methyltransferase 2D) • RNF43 (Ring Finger Protein 43) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • MSH3 (MutS Homolog 3) • GNAS (GNAS Complex Locus) • RSPO3 (R-Spondin 3) • CA 19-9 (Cancer antigen 19-9)
    |
    TP53 mutation • KRAS mutation • TMB-H • MSI-H/dMMR • HER-2 overexpression • PTEN mutation • MET overexpression • KRAS wild-type • RAS wild-type • MET expression • CCNE1 overexpression • RNF43 mutation • MGMT underexpression • NTRK expression
    |
    Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • leucovorin calcium